Corporate Profile

Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Our product development programs target specific subsets of cancer, and we seek to simultaneously develop, with partners, companion diagnostics that direct our product candidates to the patients most likely to benefit from their use. We believe this approach to personalized medicMore >>

Stock Chart
Stock chart for: 03NA000000CLVS
Stock Quote
CLVS (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Change (%) Stock is Down 0.28 (1.97%)
Intraday High$14.37
Intraday Low$13.88
Data as of 07/25/16 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
06/06/16Clovis Oncology Presents Data from Phase 2 Studies of Rucaparib in Advanced Ovarian Cancer and Pancreatic Cancer at 2016 ASCO Annual Meeting
BOULDER, Colo.--(BUSINESS WIRE)--Jun. 6, 2016-- Clovis Oncology (NASDAQ:CLVS) announced updated phase 2 results from Part 1 of the ongoing ARIEL2 study in patients with advanced ovarian cancer as well as the final results of the RUCAPANC study of rucaparib in pancreatic cancer at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Rucaparib is the Company’s oral, potent, small molecule inhibitor of PARP1, PARP2 and PARP3 ... 
Printer Friendly VersionDownload PDF
05/19/16Clovis Oncology Announces Data Presentations at 2016 ASCO Annual Meeting
New rucaparib data to be highlighted in poster presentations Rolling New Drug Application (NDA) submission for rucaparib for the treatment of patients with advanced ovarian cancer expected to complete during Q2 2016 European Marketing Authorization Application (MAA) planned in Q4 2016 BOULDER, Colo.--(BUSINESS WIRE)--May 19, 2016-- Clovis Oncology, Inc. (NASDAQ: CLVS) today announced its presen... 
Printer Friendly VersionDownload PDF
05/05/16Clovis Oncology Announces Q1 2016 Operating Results and Corporate Update
Rucaparib rolling NDA submission initiated for treatment of patients with advanced ovarian cancer with deleterious BRCA mutated tumors and expected to complete Q2 2016 Rucaparib MAA submission planned Q4 2016 Clovis preparing for potential U.S. commercial launch of rucaparib with existing commercial infrastructure in Q4 2016 or Q1 2017 ARIEL3 pivotal rucaparib maintenance study target enrollment... 
Printer Friendly VersionDownload PDF
Upcoming EventsMore >>
There are currently no events scheduled.
Receive Email AlertsEmail Alert Icon
Sign up to receive email alerts whenever Clovis Oncology, Inc. posts new information to the site. Just enter your email address and click Submit.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.